Revenue rises 52 percent and quarterly profit jumps 149 percent

Revenue Growth 20pctPat Growth 25pctEbitda Margin ExpansionResults View source PDF Explain this filing

SAKAR · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-7.5%Reaction day

₹954.00

prior close

₹937.40

announcement price

In-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-2.3%-5.1% vs market

Pharmaceuticals peers, median of 170sector-1.5%-5.9% vs sector

On the reaction day the stock moved 5.1 pts less than Nifty Microcap 250 and 5.9 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.2

10m

-5.3

15m

-4.7

30m

-6.8

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-7.5-2.3-5.1-1.5-5.9

Next day

+3.1-1.9+5.1-0.5+3.6

-1.9-0.2-1.6+1.5-3.4

+4.2-0.2+4.4+2.5+1.8

-0.3+0.5-0.8+2.7-3.0

-1.6pendingpending+1.6-3.1

—————

15d

—————

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 170Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

For the quarter ended 30 September 2026, revenue from operations was Rs 8,741.61 lakh, up 51.9 percent from Rs 5,756.04 lakh. Net profit was Rs 1,130.69 lakh versus Rs 453.98 lakh, up 149.1 percent. Earnings per share rose to Rs 5.08 from Rs 2.03, while half-year operating cash flow was positive at Rs 2,345.64 lakh. The limited review reported no material misstatement.

Likely market impact

Strong revenue and profit growth, wider margins and positive operating cash flow support sentiment, though low cash and inventory need monitoring.